Paysign (PAYS) investor relations material

Business overview and market position

• Operates two main healthcare services: plasma payments and pharmaceutical patient affordability.

• Holds approximately 45.5% market share in the U.S. plasma payments sector, making it the largest provider.

• Patient affordability (pharma co-pay) business has seen over 85% revenue growth in the first half of the year.

• Both businesses leverage a single operational platform for efficiency and regulatory compliance.

• Maintains strong competitive barriers through in-house processing, regulatory expertise, and integrated solutions.

Financial performance and guidance

• 2025 revenue reached $82 million, marking the fifth consecutive year of double-digit growth.

• Guidance for 2026 projects revenue of $114–$117 million, a +40% increase.

• Adjusted EBITDA last year was nearly $20 million, up 107%, with guidance of $35–$38 million for this year.

• SG&A growth (31%) trailed revenue growth, leading to expanded operating margins.

• High gross margins (59.4% last year, 60–62% guidance) and no bank debt, with over $30 million in unrestricted cash.

Patient affordability (pharma co-pay) business

• Provides transparent, transaction-based pricing and onshore, 24/7 customer support.

• Saved pharmaceutical clients over $325 million last year by mitigating maximizer activity; expects over $500 million in savings this year.

• 97% efficacy in identifying maximizer transactions on first fill, a key competitive advantage.

• Revenue model includes setup fees, monthly management, per-claim, and call center fees.

• Seasonality impacts revenue, with higher volumes in the first half of the year.